Zoetis Inc. (NYSE:ZTS) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 3.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 54,167 shares of the company’s stock after selling 1,746 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Zoetis were worth $8,825,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Callahan Advisors LLC increased its position in Zoetis by 90.4% in the fourth quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock worth $2,135,000 after buying an additional 6,221 shares during the period. Pensionfund Sabic grew its position in shares of Zoetis by 55.6% during the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock worth $1,825,000 after acquiring an additional 4,000 shares during the last quarter. PFW Advisors LLC acquired a new stake in shares of Zoetis in the 4th quarter worth about $1,764,000. CIBC Asset Management Inc lifted its position in Zoetis by 24.1% in the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock valued at $38,617,000 after purchasing an additional 46,050 shares during the last quarter. Finally, Alberta Investment Management Corp boosted its stake in Zoetis by 2,050.0% during the 4th quarter. Alberta Investment Management Corp now owns 30,100 shares of the company’s stock valued at $4,904,000 after purchasing an additional 28,700 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

NYSE:ZTS opened at $167.58 on Friday. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The business’s 50-day moving average price is $166.30 and its 200 day moving average price is $177.30. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53. The firm has a market cap of $75.04 billion, a P/E ratio of 30.64, a PEG ratio of 2.78 and a beta of 0.90.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. As a group, sell-side analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.19%. Zoetis’s dividend payout ratio is currently 36.56%.

Analyst Ratings Changes

Several brokerages have commented on ZTS. Leerink Partners initiated coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. Barclays raised their target price on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Morgan Stanley reduced their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Piper Sandler raised their price target on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Thursday. Finally, Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Two research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Zoetis currently has an average rating of “Buy” and an average target price of $215.90.

Insider Activity

In other news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.16% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.